Friday, 20 November 2026European Markets

POXEL Stock Bullish Momentum With A 14.97% Rise On Monday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - the market ended the session with poxel (poxel.pa) jumping 14.97% to €0.48 on monday while cac 40 dropped 0.1% to €8,019.73.

poxel's last close was €0.42, 56.05% under its 52-week high of €0.95.

about poxel

poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash); pxl065, an earlier stage programs that is in phase 2 for the treatment of nash focusing on chronic and rare metabolic indications. the company has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. poxel s.a. was incorporated in 2009 and is headquartered in lyon, france.

earnings per share

as for profitability, poxel has a trailing twelve months eps of €-1.08.

revenue growth

year-on-year quarterly revenue growth grew by 1050.6%, now sitting on 1.55m for the twelve trailing months.

volume

today's last reported volume for poxel is 428293 which is 67.76% above its average volume of 255297.

more news about poxel (poxel.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 11 Mar 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›